These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28716573)

  • 1. HtrA3 stromal expression is correlated with tumor budding in stage II colorectal cancer.
    Forse CL; Rahimi M; Diamandis EP; Assarzadegan N; Dawson H; Grin A; Kennedy E; O'Connor B; Messenger DE; Riddell RH; Kirsch R; Karagiannis GS
    Exp Mol Pathol; 2017 Aug; 103(1):94-100. PubMed ID: 28716573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor budding at the invasive front of colorectal cancer may not be associated with the epithelial-mesenchymal transition.
    Yamada N; Sugai T; Eizuka M; Tsuchida K; Sugimoto R; Mue Y; Suzuki M; Osakabe M; Uesugi N; Ishida K; Otsuka K; Matsumoto T
    Hum Pathol; 2017 Feb; 60():151-159. PubMed ID: 27836787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer.
    Zhao J; Zhang J; Zhang X; Feng M; Qu J
    Oncotarget; 2016 Jun; 7(26):40725-40734. PubMed ID: 27166271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.
    Karagiannis GS; Treacy A; Messenger D; Grin A; Kirsch R; Riddell RH; Diamandis EP
    Mol Oncol; 2014 Oct; 8(7):1240-52. PubMed ID: 24812030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer.
    Sandberg TP; Stuart MPME; Oosting J; Tollenaar RAEM; Sier CFM; Mesker WE
    BMC Cancer; 2019 Mar; 19(1):284. PubMed ID: 30922247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.
    Galván JA; Helbling M; Koelzer VH; Tschan MP; Berger MD; Hädrich M; Schnüriger B; Karamitopoulou E; Dawson H; Inderbitzin D; Lugli A; Zlobec I
    Oncotarget; 2015 Jan; 6(2):874-85. PubMed ID: 25528769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors.
    Celesti G; Di Caro G; Bianchi P; Grizzi F; Basso G; Marchesi F; Doni A; Marra G; Roncalli M; Mantovani A; Malesci A; Laghi L
    Gastroenterology; 2013 Sep; 145(3):647-57.e15. PubMed ID: 23684708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.
    Konishi Y; Kawamata F; Nishihara H; Homma S; Kato Y; Tsuda M; Kohsaka S; Einama T; Liu C; Yoshida T; Nagatsu A; Tanino M; Tanaka S; Kawamura H; Kamiyama T; Taketomi A
    Med Oncol; 2018 Jun; 35(7):104. PubMed ID: 29892782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-expression of cytokeratin and vimentin in colorectal cancer highlights a subset of tumor buds and an atypical cancer-associated stroma.
    Meyer SN; Galván JA; Zahnd S; Sokol L; Dawson H; Lugli A; Zlobec I
    Hum Pathol; 2019 May; 87():18-27. PubMed ID: 30794893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high-temperature requirement factor A3 (HtrA3) is associated with acquisition of the invasive phenotype in oral squamous cell carcinoma cells.
    Moriya Y; Uzawa N; Morita T; Mogushi K; Miyaguchi K; Takahashi K; Michikawa C; Sumino J; Tanaka H; Harada K
    Oral Oncol; 2015 Jan; 51(1):84-9. PubMed ID: 25456008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas.
    Attramadal CG; Kumar S; Boysen ME; Dhakal HP; Nesland JM; Bryne M
    Anticancer Res; 2015 Nov; 35(11):6111-20. PubMed ID: 26504037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5.
    Sadek SA; A Rehim DM; Fatima S
    Indian J Pathol Microbiol; 2020; 63(1):32-37. PubMed ID: 32031119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inter- and intra-tumoral relationships between vasculature characteristics, GLUT1 and budding in colorectal carcinoma.
    Mezheyeuski A; Nerovnya A; Bich T; Tur G; Ostman A; Portyanko A
    Histol Histopathol; 2015 Oct; 30(10):1203-11. PubMed ID: 25811313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor budding in colorectal cancer--ready for diagnostic practice?
    Koelzer VH; Zlobec I; Lugli A
    Hum Pathol; 2016 Jan; 47(1):4-19. PubMed ID: 26476568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
    Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
    Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
    Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
    J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pan-Cancer Analysis to Provide Insight into the Immunological Role and Prognostic Value of HTRA3.
    Xu Q; Wang J; Wang J; Zhu Y; Chen B; Guo R; Qian Y; Yuan H; Liu F
    Crit Rev Eukaryot Gene Expr; 2023; 33(8):57-75. PubMed ID: 37606164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.
    Koelzer VH; Herrmann P; Zlobec I; Karamitopoulou E; Lugli A; Stein U
    BMC Cancer; 2015 Mar; 15():160. PubMed ID: 25884643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.